ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-pxxiv.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-pxxiv.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1321.xmlAvastin for Breast Cancer, 2005-2011: Requiescat in Pacem?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1321.pdf2026-04-18Avastin for Breast Cancer, 2005-2011: Requiescat in Pacem?https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-pxxxv.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-pxxxv.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-pxxv.xmlErratum2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-pxxv.pdf2026-04-18Erratumhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1358.xmlOccult Primary2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1358.pdf2026-04-18Occult Primaryhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1415.xmlGene Expression Analysis and Immunohistochemistry in Evaluation of Cancer of Unknown Primary: Time for a Patient-Centered Approach2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1415.pdf2026-04-18Gene Expression Analysis and Immunohistochemistry in Evaluation of Cancer of Unknown Primary: Time for a Patient-Centered Approachhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1406.xmlCarcinoma of Unknown Primary: Focused Evaluation2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1406.pdf2026-04-18Carcinoma of Unknown Primary: Focused Evaluationhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1397.xmlManagement of Neuroendocrine Tumors of Unknown Origin2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1397.pdf2026-04-18Management of Neuroendocrine Tumors of Unknown Originhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1335.xmlCrizotinib and Testing for ALK2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1335.pdf2026-04-18Crizotinib and Testing for ALKhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1343.xmlEffort Tracking Metrics Provide Data for Optimal Budgeting and Workload Management in Therapeutic Cancer Clinical Trials2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1343.pdf2026-04-18Effort Tracking Metrics Provide Data for Optimal Budgeting and Workload Management in Therapeutic Cancer Clinical Trialshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1331.xmlThe Changing Paradigm of Treating Pancreatic Neuroendocrine Tumors2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1331.pdf2026-04-18The Changing Paradigm of Treating Pancreatic Neuroendocrine Tumorshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1328.xmlIncorporation of Crizotinib into the NCCN Guidelines2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/12/article-p1328.pdf2026-04-18Incorporation of Crizotinib into the NCCN Guidelineshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_6/article-pS-1.xmlNCCN Molecular Testing White Paper: Effectiveness, Efficiency, and Reimbursement2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_6/article-pS-1.pdf2026-04-18NCCN Molecular Testing White Paper: Effectiveness, Efficiency, and Reimbursement